NIH Releases Updates on Use of Bebtelovimab

December 29, 2022

Due to the increasing prevalence of SARS-CoV-2 Omicron subvariants that are anticipated to be resistant to bebtelovimab (i.e., BQ.1, BQ.1.1, XBB), bebtelovimab is not currently authorized by the Food and Drug Administration for the treatment of COVID-19 in any region of the United States. The COVID-19 Treatment Guidelines Panel (the Panel) recommends against the use of bebtelovimab for the treatment of nonhospitalized patients with COVID-19 who are at high risk of progressing to severe COVID-19.

The Panel has revised several sections of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines to reflect this recommendation, including Therapeutic Management of Nonhospitalized Adults With COVID-19 and Therapeutic Management of Nonhospitalized Children With COVID-19. For a complete list of updated sections, please see What's New in the Guidelines on the COVID-19 Treatment Guidelines website.